Fine-Tuning Targeted Therapy For Multiple Myeloma With ‘Multi-Omics’ Data
Alessandro Lagana, PhD, discusses a study in which researchers from the Icahn School of Medicine at Mount Sinai analyzed biological data sets from multiple myeloma patients to develop a computational model for identifying high-risk patients who can serve as ideal drug candidates. He said, “Information gained from MM-PSN showed the advantages of employing multiple data types to associate myeloma patients into more granular and homogeneous subtypes than achieved by previous classifications.”
Mount Sinai Researchers Discover Genes That Predict Good Response to Blood Cancer Therapy
Jun 16, 2022 View All Press ReleasesModel May Better Classify Multiple Myeloma and Relapse Risks
Jan 17, 2022 View All Press Releases
Scientists Identify New Types of a Blood Cancer and Potential Targeted Treatments
Nov 17, 2021 View All Press Releases